Verrica Pharmaceuticals Inc Cash Flow Conversion Efficiency
Verrica Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Verrica Pharmaceuticals Inc (VRCA) has a cash flow conversion efficiency ratio of -2.154x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.28 Million) by net assets ($4.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Verrica Pharmaceuticals Inc (2016–2025)
Cash flow conversion efficiency of Verrica Pharmaceuticals Inc from 2016 to 2025. This chart illustrates how Verrica Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Verrica Pharmaceuticals Inc (VRCA) share price today for real-time trading data and today's change.
Verrica Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Verrica Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Verrica Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Verrica Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see VRCA company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chin Yang Ind
KO:003780
|
0.034x |
|
JD Sports Fashion PLC
LSE:JD
|
0.128x |
|
ICH Co Ltd
KQ:368600
|
-0.014x |
|
MGI Digital
PA:ALMDG
|
0.015x |
|
Shanghai Yaohua Pilkington Glass Group Co Ltd B
SHG:900918
|
0.039x |
|
BP Plastics Holding Bhd
KLSE:5100
|
0.020x |
|
Atinum Investment Co. Ltd
KQ:021080
|
0.098x |
|
Saehwa IMC Co Ltd
KO:145210
|
0.026x |
Annual Cash Flow Conversion Efficiency for Verrica Pharmaceuticals Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Verrica Pharmaceuticals Inc from 2016 to 2025. Review Verrica Pharmaceuticals Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $24.74 Million | $-17.63 Million | -0.712x | -111.53% |
| 2024-12-31 | $-9.86 Million | $-60.93 Million | 6.179x | +416.56% |
| 2023-12-31 | $19.76 Million | $-38.58 Million | -1.952x | -319.00% |
| 2022-12-31 | $40.03 Million | $-18.65 Million | -0.466x | +44.93% |
| 2021-12-31 | $32.60 Million | $-27.58 Million | -0.846x | +7.62% |
| 2020-12-31 | $32.99 Million | $-30.21 Million | -0.916x | -117.23% |
| 2019-12-31 | $65.02 Million | $-27.41 Million | -0.422x | -110.92% |
| 2018-12-31 | $89.43 Million | $-17.87 Million | -0.200x | -130.71% |
| 2017-12-31 | $-7.04 Million | $-4.58 Million | 0.651x | +7.64% |
| 2016-12-31 | $-2.66 Million | $-1.61 Million | 0.605x | -- |
About Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the tr… Read more